Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

SHOCKING: Aerie pharmaceuticals | Mind Blowing Facts

Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022

Upgrades

Benzinga · Aug 29, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022

Benzinga · Aug 24, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2022

Benzinga · Aug 23, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Benzinga · Aug 1, 2022

Aerie Pharmaceuticals Begins Patient Dosing In Late-Stage Dry Eye Disease Study

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has dosed the first patient in the Phase 3 COMET-2 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).

Benzinga · May 24, 2022

HC Wainwright & Co. Maintains Buy Rating for Aerie Pharmaceuticals: Here's What You Need To Know

HC Wainwright & Co. has decided to maintain its Buy rating of Aerie Pharmaceuticals (NASDAQ:AERI) and lower its price target from $25.00 to $20.00. Shares of Aerie Pharmaceuticals are trading down 3.54% over the last 24 hours, at $6.03 per share.

Benzinga · May 9, 2022

Earnings Preview For Aerie Pharmaceuticals

Aerie Pharmaceuticals (NASDAQ:AERI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Aerie Pharmaceuticals will report an earnings per share (EPS) of $-0.65.

Benzinga · May 4, 2022

Read news from The Economist, FT, and more,
with one subscription

Recap: Aerie Pharmaceuticals Q4 Earnings

Aerie Pharmaceuticals (NASDAQ:AERI) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · Feb 24, 2022

Coverage From

Benzinga

Organisations

Food and Drug Administration

US Food and Drug Administration

63 stories

AutoNation

59 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

420,586 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.